NCT05855941View on ClinicalTrials.gov

Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

May 31, 2032

Study Completion Date

May 31, 2032

Conditions
Cervix CancerEndometrial CancerEpithelial Ovarian Cancer
Interventions
DIAGNOSTIC_TEST

FDG-PET/CT and FDG-PET/MRI

Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.

Trial Locations (1)

Unknown

RECRUITING

Centre for Gynecology and Obstetrics, Umea University Hospital, Umeå

All Listed Sponsors
collaborator

Umeå University

OTHER

lead

Region Västerbotten

OTHER_GOV